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Ovarian cancer is a component of the autosomal-dominant hereditary breast-ovarian cancer syndrome and may
be due to a mutation in either the BRCA1 or BRCA2 genes. Two mutations in BRCA1 (185delAG and 5382insC)
and one mutation in BRCA2 (6174delT) are common in the Ashkenazi Jewish population. One of these three
mutations is present in ∼2% of the Jewish population. Each mutation is associated with an increased risk of ovarian
cancer, and it is expected that a significant proportion of Jewish women with ovarian cancer will carry one of these
mutations. To estimate the proportion of ovarian cancers attributable to founding mutations in BRCA1 and BRCA2
in the Jewish population and the familial cancer risks associated with each, we interviewed 213 Jewish women
with ovarian cancer at 11 medical centers in North America and Israel and offered these women genetic testing
for the three founder mutations. To establish the presence of nonfounder mutations in this population, we also
completed the protein-truncation test on exon 11 of BRCA1 and exons 10 and 11 of BRCA2. We obtained a
detailed family history on all women we studied who had cancer and on a control population of 386 Ashkenazi
Jewish women without ovarian or breast cancer. A founder mutation was present in 41.3% of the women we
studied. The cumulative incidence of ovarian cancer to age 75 years was found to be 6.3% for female first-degree
relatives of the patients with ovarian cancer, compared with 2.0% for the female relatives of healthy controls
(relative risk 3.2; 95% CI 1.5–6.8; ). The relative risk to age 75 years for breast cancer among the femaleP = .002
first-degree relatives was 2.0 (95% CI 1.4–3.0; ). Only one nonfounder mutation was identified (in thisP = .0001
instance, in a woman of mixed ancestry), and the three founding mutations accounted for most of the observed
excess risk of ovarian and breast cancer in relatives.
Introduction
Ovarian cancer is among the most common forms of
hereditary cancer in adults and is the leading cause of
death caused by gynecological malignancy in North
America. Both reproductive and genetic factors have
been implicated in ovarian-cancer etiology (Risch 1998),
and a family history of ovarian cancer is among the
strongest risk factors for the disease (Amos and Struew-
ing 1993). The familial breast-ovarian cancer syndrome
accounts for ∼5% of all ovarian cancer cases in Canada
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(Narod et al. 1994). The majority of families with this
syndrome carry a mutation in BRCA1 (MIM 113705)
or BRCA2 (MIM 600185) (Narod et al. 1995a, 1995b).
The lifetime risk of ovarian cancer conferred by a
BRCA1 mutation has been estimated to be 60% (Ford
et al. 1994; Easton et al. 1995), and the risk for carriers
of a BRCA2 mutation has been estimated to be 27%
(Ford et al. 1998). These risks greatly exceed the pop-
ulation risk of 1.4% by age 70 years. However, these
cumulative risk estimates are made on the basis of stud-
ies of families with multiple instances of early-onset
breast or ovarian cancer; a risk estimate made on the
basis of a sample of (mostly) unaffected Jewish individ-
uals was much lower (Struewing et al. 1997). The risks
conferred by BRCA1 or BRCA2 mutations, ascertained
through women with cancer but unselected for family
history, may also be different. The cancer risks in carriers
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Table 1
Frequency of Mutations in Cases of Ovarian Cancer by
Age at Diagnosis
AGE
GROUP
(YEARS)
TOTAL
NO. OF
PATIENTS
NO. (%) POSITIVE
FOR MUTATION IN
BRCA1 BRCA2 Either
19–29 3 0 (.0) 0 (.0) 0 (.0)
30–39 15 7 (46.7) 1 (6.7) 8 (53.3)
40–49 54 24 (44.4) 2 (3.7) 26 (48.1)
50–59 43 15 (34.9) 8 (18.6) 23 (53.5)
60–69 49 9 (18.4) 10 (20.4) 19 (38.8)
70–90 44 2 (4.5) 8 (18.2) 10 (22.7)
Total 208 57 (27.4) 29 (13.9) 86 (41.3)
Table 2
Frequency of Mutations in Cases of Ovarian Cancer by Histology
HISTOLOGY
TOTAL
NO. OF
PATIENTS
NO. (%) POSITIVE
FOR MUTATION IN
BRCA1 BRCA2 Either
Serous 105 33 (31.4) 18 (17.1) 51 (48.6)
Mullerian or mixed 21 6 (28.6) 3 (14.3) 9 (42.9)
Endometrioid 12 3 (25.0) 3 (25.0) 6 (50.0)
Mucinous 7 1 (14.3) 0 (.0) 1 (14.3)
Clear cell 7 1 (14.3) 0 (.0) 1 (14.3)
Transitional cell 1 0 (.0) 0 (.0) 0 (.0)
Brenner 1 0 (.0) 0 (.0) 0 (.0)
Total 154 44 (28.6) 24 (15.6) 68 (44.2)
NOTE.—Eighteen carriers and 36 noncarriers had missing histology
information.
may also vary by specific mutation and among ethnic
groups.
In North America, the incidence of ovarian cancer is
higher among Ashkenazi Jewish women than among
Sephardic Jewish women or non-Jewish women. The
rate of ovarian cancer among Israeli Jews born in Eu-
rope or North America is among the highest reported
and greatly exceeds the rate for Israeli non-Jews (Parkin
et al. 1997). We hypothesize that the excess risk of ovar-
ian cancer observed in the Jewish population might be
predominantly due to a high prevalence of mutations
in the ovarian cancer–susceptibility genes BRCA1 and
BRCA2. Three common mutations are reported in this
population: two in BRCA1 (185delAG and 5382insC)
(Struewing et al. 1995a; Roa et al. 1996) and one in
BRCA2 (6174delT; Oddoux et al. 1996). The combined
frequency of these three mutations in the Ashkenazi
population is ∼2% (reviewed in Tonin et al. 1996).
It is important to measure directly the proportion of
ovarian cancers in Jewish women that are attributable
to mutations for the purposes of genetic counseling,
screening, and prevention. We interviewed a total of 213
Ashkenazi Jewish women with ovarian cancer, unse-
lected for age or family history, from 11 hospitals in
North America and Israel, and we evaluated 208 of
these women for the presence of a founding mutation
in BRCA1 or BRCA2.
Materials and Methods
Data Collection
Study population.—A hospital-based study of Jewish
women with epithelial ovarian cancer was conducted
among 11 centers in North America and Israel. Two
hundred Jewish women with ovarian cancer were re-
cruited from the Departments of Gynecology and On-
cology of the collaborating hospitals. In some hospitals,
religious affiliation was recorded on the medical record.
In other hospitals, the patient lists were reviewed for
patients who were known to be of Jewish ancestry by
the treating physician or who were likely to be Jewish
by surname. The treating physicians were then asked to
write letters to the selected patients and request their
permission for a member of the study team to contact
them. The letter described the study goals and offered
the patient an opportunity to participate. The patient
was then contacted by a member of the study team and
was interviewed by telephone or in person for her family
history and risk-factor profile. Patients confirmed that
they were Jewish by birth (i.e., they were not adopted
and had not converted). The study protocol also in-
cluded the collection of a blood sample for genetic test-
ing. Patients who wished to participate in the genetic
testing protocol were given pretest counseling by a mem-
ber of the study team or by the genetic counselor affil-
iated with the host institution. Patients were offered the
option of receiving the results of the genetic tests, and
most indicated their willingness to receive the results.
We were able to obtain a copy of the pathology report
from 85% of these patients. Pathology reports were re-
viewed for tumor stage (Fe´de´ration Internationale de
Gyne´cologie et d’Obstetrique classification), for grade,
and for histologic subtype.
An additional 13 study subjects were identified
through the Ontario Cancer Registry as part of a prov-
incewide study of genetic factors in ovarian cancer. These
patients were all incident cases of ovarian cancer diag-
nosed in the province between 1995 and 1996 and who
indicated on the questionnaire that they were of Jewish
ancestry.
A total of 465 potential study subjects were identified.
Of these, 80 subjects were dead, and it was not possible
to locate 98 women. A further 33 patients were excluded
because review of the pathology report indicated a di-
agnosis other than invasive epithelial ovarian cancer. Of
the total of 254 women who were approached to par-
ticipate, 213 agreed to complete the family history ques-
tionnaire, and 208 agreed to provide a blood sample for
genetic testing. Forty-nine subjects refused to participate;
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Table 3
Frequency of Mutations in Cases of Ovarian Cancer by Stage
and Grade
STAGE OR
GRADE
TOTAL
NO. OF
PATIENTS
NO. (%) POSITIVE
FOR MUTATION IN
BRCA1 BRCA2 Either
Stage:
I 30 6 (20.0) 2 (6.7) 8 (26.7)
II 15 7 (46.7) 2 (13.3) 9 (60.0)
III 120 32 (26.7) 23 (19.2) 55 (45.8)
IV 11 5 (45.5) 0 (.0) 5 (45.5)
Total 176 50 (28.4)a 27 (15.3)b 77 (43.8)c
Grade:
I 13 1 (7.7) 0 (.0) 1 (7.7)
II 22 1 (4.5) 4 (18.2) 5 (22.7)
III 128 47 (36.7) 19 (14.8) 66 (51.6)
Total 136 49 (30.1)d 23 (14.1)e 72 (44.2)f
NOTE.—Nine carriers and 21 noncarriers had missing stage
information, whereas 14 carriers and 28 noncarriers had missing
grade information.
a Overall .P = .40
b Overall .P = .34
c Overall .P = .15
d Overall .P = .001
e Overall .P = .31
f Overall .P = .0002
Figure 1 Cumulative incidence of ovarian cancer to age 75 years in female first-degree relatives of women with cancer and control women.
We observed 20 ovarian cancers among the 638 female relatives of women with ovarian cancer and 10 ovarian cancers among the 1,130 female
relatives of control women ( ).P = .0015
16 were ill, 8 were concerned about the insurance im-
plications of genetic testing, 3 did not speak English, 2
were part of other genetic studies, and 2 were concerned
that participating would be stressful. For 18 patients,
the reason of refusal was not specified.
Epidemiological information and demographic infor-
mation were collected by questionnaire, and a detailed
family history was taken by interview. The questionnaire
inquired about the patient’s ethnic origin and the birth-
place of her parents and grandparents. Three-generation
pedigrees were drawn to include all women with breast
and ovarian cancer. The current age (or the age of death)
of all first-degree relatives was recorded on the pedigree.
The ages at diagnosis and the sites of cancer were ob-
tained for affected relatives. The diagnosis of cancer in
the proband was confirmed by review of pathology re-
ports, but in general, it was not possible to confirm can-
cer in relatives.
Control population.—Control women were used in or-
der to evaluate the importance of family history for ovar-
ian cancer in Jewish women. The control population
comprised Jewish women with no history of breast or
ovarian cancer, and they were selected from two sources.
First, staff members of several of the collaborating hos-
pitals were approached to participate. These controls
included 126 paid and unpaid employees of the Toronto
Hospital, the Montreal Jewish General Hospital, the Ce-
dars-Sinai Hospital, the Columbia Presbyterian Medical
Center, the Albert Einstein Medical Center, the Central
Emek Hospital, and the Yale University Medical Center.
A second group of 260 control women was obtained by
sending a mailed invitation to women on the member-
ship lists of a Toronto synagogue and a Jewish women’s
group. Control women were aware that they were par-
ticipating in a study of breast and ovarian cancer, but
1262 Am. J. Hum. Genet. 66:1259–1272, 2000
Table 4
Frequency of Mutations in Women with Ovarian Cancer by Family History
FAMILY HISTORY
TOTAL
NO. OF
PATIENTS
NO. (%) POSITIVE FOR MUTATION
IN
BRCA1 BRCA2 Either
None 119 23 (19.3) 10 (8.4) 33 (27.7)
Breast cancer (no relatives with ovarian cancer):
1 instance of breast cancer under age 50 years 27 12 (44.4) 3 (11.1) 15 (55.6)
2 instances of breast cancer under age 50 years 8 6 (75.0) 1 (12.5) 7 (87.5)
Ovarian cancer (no relatives with breast cancer):
1 instances of ovarian cancer 30 9 (30.0) 9 (30.0) 18 (60.0)
Breast and ovarian cancer
1 instance of breast cancer under age 50 years 9 5 (55.6) 2 (22.2) 7 (77.8)
2 instances of breast cancer under age 50 years 6 2 (33.3) 2 (33.3) 4 (66.7)
NOTE.—Nine women had missing information on second-degree relatives, so they are not included in
this table.
they were unaware that family history was the principal
factor under study. The control women provided a de-
tailed family history, but they did not supply a blood
sample for genetic testing.
Mutation Analysis
High-molecular-weight DNA was extracted from
whole blood. Red blood cells were lysed by absorbing
to ammonium ions in red-blood-cell lysis buffer. The
leukocytes were isolated and stored at 70C. Leuko-
cytes were then digested by adding buffer (NaCl and
EDTA), 100 ml of 20 mg/ml proteinase K, 4 ml of 1 U/
ml ribonuclease A, and 250 ml of 20% SDS to this so-
lution. DNA was then extracted by the standard phen-
ylchloroform procedures. Exons 2 and 20 in the BRCA1
gene and exon 11 in the BRCA2 gene were amplified
by standard PCR amplification protocols. Exon 20 of
BRCA1 was evaluated for 5382insC mutations by SSCP
analysis, and exon 2 of BRCA1 was evaluated for
185delAG mutations by heteroduplex analysis.
The protein-truncation test was used to screen for
truncating mutations in exon 11 of BRCA1 and exons
10 and 11 of BRCA2. Truncating mutations in these
exons represent ∼70% of the mutations found to date
in families with deleterious mutations in these genes. A
protein-truncation test of exon 11 is also used to identify
the abnormal band corresponding to the BRCA2
6174delT mutation.
The aberrant bands generated by each of these tech-
niques were sequenced by annealing 5 ml exon 2 (delAG)
PCR product, 1 ml exon 20 (insC), and 7 ml exon 11
(delT) PCR products to template and primers and se-
quenced by a standard protocol as outlined in Amer-
sham sequencing kits US70170 and US79750. All sam-
ples were tested for all three founder mutations, and each
mutant was confirmed by direct sequencing.
Statistical Analysis
Each case of ovarian cancer was classified as familial
or nonfamilial on the basis of the presence of one case
of ovarian cancer (other than the proband) or two cases
of early-onset breast cancer (defined as !50 years of age
at diagnosis) in the first- and second-degree relatives of
the proband. The proportion of individuals with and
without mutations was calculated by age at onset; by
histologic type, grade, and stage; and for familial and
nonfamilial instances.
We compared the cancer risks among the relatives of
the women with ovarian cancer and the relatives of the
Jewish control women without cancer. To do this, the
cumulative incidence of breast and ovarian cancer was
calculated for all first-degree relatives of the affected
women and control women. Each relative was consid-
ered to be at risk for cancer from birth until either they
developed cancer or until death. The cumulative cancer
risks were calculated by means of an actuarial survival
method, and the significance was assessed with the log-
rank test. The relative risk (RR) for cancer was then
estimated by comparison of the incidence rates for the
relatives of the ovarian-cancer patients with the relatives
of controls by use of a Cox proportional-hazards model.
Risks were calculated for the entire patient population
and then separately for the subgroups of women with
BRCA1 or BRCA2 mutations. Because we recorded can-
cer histories on all first-degree relatives, we were able to
estimate the penetrance of breast and ovarian cancer for
each of the three mutations by making use of the kin-
cohort method of Wacholder et al. (1998). The method
is based on the assumption that half of the first-degree
relatives of the mutation carriers are also expected to be
carriers and that relatives are also at risk of carrying a
different mutation, consistent with the population
estimates.
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Figure 2 Cumulative incidence of breast cancer to age 75 years in female first-degree relatives of women with cancer and control women.
We observed 63 breast cancers among the 638 female relatives of cases with ovarian cancer and 50 breast cancers among the 1,130 female
relatives of control women ( ).P ! .0001
Results
A total of 213 cases of epithelial ovarian cancer were
collected from 11 different medical centers. These rep-
resent the majority of living cases of ovarian cancer in
Jewish women under active follow-up at the depart-
ments of gynecology and oncology of the 11 partici-
pating hospitals. Our study attempted to recruit all prev-
alent cases, and the median time since diagnosis was 2.2
years (range, 0–25.6 years). The average age at diagnosis
of ovarian cancer was 57.6 years (range 19–88 years),
and the average age of the women at the time of the
interview was 61.2 years (range 21–90 years).
A total of 86 founder mutations was found among
the 208 patients (41.3%), including 57 in BRCA1 (43
in 185delAG and 14 in 5382insC) and 29 in BRCA2
(6174delT). The frequency of mutations varied by age
at onset (table 1); a BRCA1 mutation was found in
41.1% of women diagnosed between the ages of 30 and
60 years and in 11.8% of those diagnosed when they
were older than age 60 ( for difference). AP ! .0001
BRCA2 mutation was found in 9.8% of women diag-
nosed between the ages of 30 and 60 and in 19.4% of
women diagnosed after age 60 ( ). Women withP = .07
BRCA1 mutations were diagnosed with ovarian cancer
at a younger age, on average, than women for whom
no mutation was detected (50.8 years and 59.2 years,
respectively; ). In contrast, women withP ! .0001
BRCA2 mutations were older when they were diag-
nosed than were women for whom no mutation was
detected, but the difference was not significant (62.1
years vs. 59.2 years; ). BRCA2 mutations wereP = .27
more numerous than BRCA1 mutations in women di-
agnosed with ovarian cancer after age 60 years (18
women vs. 11 women, respectively).
The majority of mutations (75%) were found in
women with papillary serous tumors (table 2). Endom-
etrioid and Mullerian tumors were relatively uncom-
mon, but these were associated with a high mutation
frequency. In contrast, mucinous and clear-cell tumors
were underrepresented in the women who carried the
mutation. The great majority (92%) of women who
carried the mutation presented with grade III tumors
(table 3), and 52% of the women with grade III tumors
were positive for mutation. There was no difference in
the stage distribution between the mutation-positive
and mutation-negative tumors (table 3).
Patients with one relative with ovarian cancer or with
two relatives with early-onset breast cancer were clas-
sified as familial. In total, 53 of 199 women (27%) for
whom complete family histories on second-degree rel-
atives were available satisfied this definition of familial
cancer. An additional 27 patients (14%) had a single
relative with early-onset breast cancer. As expected, mu-
tations were more among familial patients than among
nonfamilial patients (table 4). Mutations were present
in 78% of the women with two or more affected rel-
atives (breast or ovarian cancer), in 58% of women with
one affected relative, and in 28% of patients with no
relative with ovarian cancer or early-onset breast cancer.
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Figure 3 Cumulative incidence of ovarian cancer to age 75 years in female first-degree relatives of carriers, noncarriers, and controls. We
observed 13 ovarian cancers among the 253 female relatives of carrier women with ovarian cancer, 7 ovarian cancers among the 368 female
relatives of noncarrier cases, and 10 ovarian cancers among the 1,130 female relatives of control women ( ).P ! .0001
A family history of one or more affected relatives was
present in 61% of the patients with a mutation.
Among the first-degree relatives of women with ovar-
ian cancer, the cumulative incidence of ovarian cancer
was estimated to be 6.3% to age 75 years. This risk
was significantly greater than the risk in relatives of the
control women (RR = 3.2; ) (fig. 1). The riskP = .002
of breast cancer to age 75 years for first-degree relatives
of the ovarian-cancer patients was also increased (RR
= 2.0; ) (fig. 2). The cumulative incidence ofP = .0001
breast cancer in the first-degree relatives of the ovarian-
cancer patients reached 20.4% at age 75 years, com-
pared with 11.3% for the relatives of the controls.
The risks of cancer in the probands’ relatives also
depended on the age at onset of the index case. Among
the female relatives of women diagnosed with ovarian
cancer before the age of 55 years, the cumulative inci-
dence of ovarian cancer to age 75 years was 11.6%,
compared with 4.4% for relatives of women diagnosed
after age 55 years (RR = 2.3; ). This was notP = .05
due to the effect of the mutation carriers; after excluding
the carriers, the risk for relatives of early-onset ovarian
cancer remained higher than the risk for relatives of
women diagnosed after age 55 years (RR = 7.4; P =
). Among relatives of early-onset ovarian cancer, the.02
cumulative incidence to age 75 years for breast cancer
was 25.7%, compared with 18.1% for the relatives of
women diagnosed after age 55 years (RR = 2.0; P =
). After excluding carriers, the RR for breast cancer.006
was 2.93 ( ).P = .02
Among the subgroup of patients with BRCA1 or
BRCA2 mutations, the familial risks were particularly
high (figs. 3 and 4). The RR of ovarian cancer to age
75 years among the female relatives ofBRCA1mutation
carriers compared with healthy control women was 5.4
(95% CI 2.4–12.3), and the RR for breast cancer was
3.2 (95% CI 2.1–4.9). There was no significant differ-
ence in risks for the two BRCA1 mutations. For the
first-degree relatives of the 29 BRCA2 carriers, the RRs
to age 75 years were 6.2 for ovarian cancer (95% CI
2.3–17.1) and 2.4 for breast cancer (95% CI 1.2–4.5).
The cumulative incidence of ovarian cancer to age 75
years was slightly higher in the relatives of carriers of
BRCA2 mutations than carriers of BRCA1 mutations
(12.3% vs. 8.3% to age 75 years), but this difference
was not statistically significant. The average age at onset
of breast cancer in the relatives of the BRCA1 carriers
was 48.7 years and was less than that of the BRCA2
carriers (57.5 years; ). The cumulative incidenceP = .06
of breast cancer to age 55 years was 18.8% for first-
degree relatives of BRCA1 carriers, compared with only
6.2% for first-degree relatives of BRCA2 carriers (P =
)..02
The excess risks of ovarian or breast cancer in the
relatives of the women, compared with that of the con-
trols, were mostly, but not entirely, attributable to the
presence of one of three founding mutations (figs. 3 and
4). Among the female relatives of women who tested
negative for all three mutations, the cumulative risk of
ovarian cancer to age 75 years was 4%, compared with
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Figure 4 Cumulative incidence of breast cancer to age 75 years in female first-degree relatives of carriers, noncarriers, and controls. We
observed 36 breast cancers among the 253 female relatives of carrier women with ovarian cancer, 27 breast cancers among the 368 female
relatives of noncarrier women, and 50 ovarian cancers among the 1,130 female relatives of control women ( ).P ! .0001
a risk of 2% in the first-degree relatives of the healthy
controls (RR = 1.9; P = .20; fig. 3). Similarly, the cu-
mulative risk of breast cancer in the relatives of the
mutation-negative women was 16%, compared with
11% for the relatives of the healthy controls (RR = 1.4;
P = .15; fig. 4).
The majority of the mutation-positive tumors was of
serous papillary histology. The cancer risks for relatives
of women with serous papillary tumors were elevated,
but those for relatives of women with other tumor types
were not (fig. 5). The RR of breast cancer among first-
degree relatives of serous papillary tumors was 2.7
( ) and was 1.2 for first-degree relatives ofP ! .001
women with other tumor types ( ). Among theP = .6
noncarrier population with serous tumors, the RR for
breast cancer was 1.73 (P = .08).
The cumulative incidence of breast and of ovarian
cancer was compared for the mothers and sisters of the
ovarian cancer patients. In the entire group of women
we studied, the risk of breast cancer was greater for
sisters (29% to age 75 years) than it was for mothers
(17% to age 75 years; ). There was no differenceP = .04
in the risk of ovarian cancer between mothers and sis-
ters. Among the subgroup of mutation-positive women,
the risk of breast cancer in the sisters (38%) moderately
exceeded that in the mothers (25%), but the difference
was not significant ( ). The risk of ovarian cancerP = .26
in the carriers’ sisters (14%) was similar to that of the
mothers (14%).
The lifetime risk of ovarian cancer in BRCA1 and
BRCA2 carriers can be estimated from our data in two
ways. First, RRs can be constructed by comparing the
frequency of mutations in women with the reported
frequencies of mutations in healthy Jewish control
women. Second, we can use the data on the observed
cases of ovarian cancer in the relatives of the carriers
to construct penetrance estimates, according to the kin-
cohort method described by Wacholder et al. (1998).
Among the 191 women diagnosed with ovarian can-
cer before age 75 years, we identified 42 carriers of the
185delAG mutation, 14 carriers of the 5382insC mu-
tation, and 26 carriers of the 6174delT mutation. The
frequencies of these mutations in North American Jews
are reported to be 7.7 per 1,000 for the 185delAG mu-
tation, 3.8 per 1,000 for the 5382insC mutation, and
11.1 per 1,000 for the 6174delT mutation (Struewing
et al. 1997). Therefore, the odds ratios for ovarian can-
cer to age 75 years are 36.6 for the 185delAG mutation,
20.8 for the 5382insC mutation, and 14.2 for the
6174delT mutation. Assuming baseline population risks
for ovarian cancer of 1.4% to age 75 years (SEER Da-
tabase, white women, 1988–1992; see Parkin et al.
1997) these risks are roughly equivalent to cumulative
incidences to age 75 years of 51.2%, 29.1%, and 19.9%
for the 185delAG, 5382insC, and 6174delT mutations,
respectively.
There were a total of 13 ovarian cancers observed
before age 75 years among the 253 female first-degree
relatives of the carriers. The relatives of the control pop-
ulation have a risk of 2.0% to age 75 years of ovarian
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Figure 5 Cumulative incidence of breast cancer to age 75 years in female first-degree relatives of women with serous and nonserous
ovarian cancer and control women. We observed 37 breast cancers among the 305 female relatives of women with serous ovarian cancer, 9
breast cancers among the 141 female relatives of women with nonserous ovarian cancer, and 50 ovarian cancers among the 1,130 female
relatives of control women ( ).P ! .0001
cancer (this risk is slightly greater than the lifetime risk
of 1.4% for women in the general population in North
America). The penetrances to age 75 years are estimated
to be 10.1%, 21.0%, and 26.6% for the 185delAG,
5382insC, and 6174delT mutations, respectively, on the
basis of the method of Wacholder et al. (1998). Because
these estimates were made on the basis of a total of 13
observed ovarian cancers, the confidence limits are
wide.
Data on the first-degree relatives of the carrier women
and the noncarrier women were also used to construct
estimates of breast-cancer penetrance. The estimated
penetrance of the BRCA1 mutations for breast cancer
was 31.3% to age 55 years, 45.9% to age 65 years, and
43.8% to age 75 years. The penetrance of the 185delAG
mutation (44.2% to age 75 years) was similar to that
of the 5382insC mutation (39.3% to age 75 years). The
estimated penetrance of breast cancer to age 75 years
for carriers of the 6174delT BRCA2 mutation was only
slightly lower (36.8% to age 75 years). However, the
difference was striking for breast cancer risk before age
55 years (31.3% for BRCA1 mutations vs. 6.1% for
BRCA2; ).P = .02
A history of cancer other than ovarian cancer was
reported by 42 of 213 women (19.7%), including
29.1% of the mutation-positive women and 12.3% of
the mutation-negative women ( for the differ-P = .003
ence). Overall, 25 of 42 women with multiple primary
cancer (59.5%) carried a BRCA1 or BRCA2 mutation,
including 18 of 25 women with a past history of breast
cancer. The other cancers in carriers included colorectal
cancer (two cases), skin cancer (three cases), head and
neck cancer (one case), and lung cancer (one case).
We assessed the risks of cancers at other sites in the
relatives of the women we studied by comparing the
cancer histories of the 1,222 first-degree relatives of the
women with ovarian cancer with the cancer histories of
the 2,213 first-degree relatives of the control women.
Because the average age of the relatives of the women
with cancer was greater than that of the relatives of the
control women (53.8 years and 48.2 years, respectively;
), a survival analysis was performed, takingP ! .0001
into account the at-risk period for each relative (see
Methods). The risks of cancer of all sites were compared
for the relatives of the women and control women (table
5).
Overall, the relatives of the women with ovarian can-
cer experienced a 74% greater risk of any cancer to age
75 years compared with controls ( ). The ex-P = .0001
cess risk was present in men (RR = 1.6; ) asP = .005
well as in women (RR = 1.9; ). The excess inP = .001
men was largely attributable to cancers of the prostate
and pancreas. Nonsignificant excesses of cancer of the
colon, head and neck, and lung were also observed.
Among the female first-degree relatives, the overall risk
of cancer to age 75 years was increased 1.9 times (95%
CI 1.4–2.4). Excluding cancer of the breast and ovary,
the RR was 1.5 (95% CI 1.0–2.1). Sites of excess in-
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Figure 6 Pedigree of the family carrying the 6696delTC muta-
tion. Circles denote women; squares denote men. Individuals affected
with cancer (blackened symbols) and unaffected individuals (unblack-
ened symbols) are both indicated. A diagonal line through a symbol
indicates that the individual denoted is dead.
Table 5
Cumulative Incidence of Cancer in First-Degree Relatives of Jewish Ovarian-Cancer Patients and Jewish Controls
SITE
CUMULATIVE INCIDENCE OF CANCER (%) TO AGE
55 Yearsa 65 Yearsa 75 Yearsa
Control Case Pb RRc Control Case Pb RRc Control Case Pb RRc
Breast 3.5 9.1 .0001 2.87 7.7 14.2 .0003 2.12 11.3 20.4 .0001 2.04
Ovary 1.0 3.9 .002 3.96 1.7 5.0 .003 3.21 2.0 6.3 .002 3.20
Prostate .0 .6 .081  .3 .6 .339 3.05 2.6 7.5 .007 3.50
Uterus .3 .6 .644 1.58 .3 1.5 .153 3.22 .6 2.2 .163 2.67
Colon .4 .8 .290 1.88 1.6 2.2 .310 1.48 3.5 5.3 .152 1.51
Pancreas .0 .4 .031  .1 1.5 .002 12.66 1.0 2.0 .027 3.15
Lung .1 .1 .756 1.55 .3 1.0 .167 2.64 2.4 3.4 .319 1.46
Head and neck .1 .1 .747 1.57 .3 .8 .316 2.11 .5 .8 .512 1.58
Melanoma .2 .2 .656 1.56 .2 .2 .656 1.56 .4 .8 .323 2.09
Primary site unknown .0 .6 .013  .3 1.0 .036 4.73 1.5 1.4 .542 1.37
Any:
Womend 3.4 5.0 .184 1.51 7.0 11.6 .026 1.67 14.6 20.2 .047 1.45
Women 7.4 16.4 .0001 2.41 15.1 27.2 .0001 2.06 25.6 40.4 .0001 1.85
Men 2.7 4.3 .234 1.49 7.4 12.0 .056 1.56 21.5 31.3 .005 1.60
All 5.1 10.6 .0001 2.13 11.5 19.9 .0001 1.88 23.6 35.9 .0001 1.74
NOTE.—Cancers in women include cancers in 1,130 female relatives of control women and 638 female relatives of probands.
Cancers in men include 1,083 male relatives of control women and 584 male relatives of probands.
a Kaplan-Meier estimates.
b Log-rank test.
c Relative risks are obtained from a univariate Cox proportional hazard model. Baseline: index controls.
d Women with no breast or ovarian cancer. Female relatives with breast cancer or ovarian cancer are considered to be at risk for
other cancers.
cluded the uterus, colon, pancreas, and lung; however,
of these, only the excess of pancreatic cancer to age 65
years was statistically significant ( ).P = .03
The cancer risks were also compared for relatives of
the mutation-positive women and mutation-negative
women (table 6). The carrier relatives were at greater
risk for breast, ovary, uterus, and prostate cancer. The
endometrial cancer excess was limited to the relatives
of the BRCA1 carriers. The RR of endometrial cancer
to age 75 years in relatives of BRCA1 carriers compared
with relatives of healthy controls was 9.4 ( ).P = .0003
However, this risk was based on only four cases of en-
dometrial cancer observed in the relatives of theBRCA1
carriers.
The cumulative incidences of prostate cancer to age
75 years were 2.6% for relatives of healthy controls,
5.3% for relatives of noncarrier cases, 8.0% for rela-
tives of BRCA1 carriers, and 12.0% for relatives of
BRCA2 carriers. The prostate cancer risk was signifi-
cantly increased for both the relatives of the BRCA1
carriers ( ) and BRCA2 carriers ( ) com-P = .01 P = .002
pared with healthy controls.
Overall, the relatives of the BRCA2 carriers were at
greater risk for cancer of any type than the relatives of
the BRCA1 carriers (46.3% vs. 34.9%; ; tableP = .35
7). The risk was significantly higher for cancer in men
before age 65 years (21.4% vs. 4.4%; ), attrib-P = .01
utable to an excess of prostate, pancreatic, and colon
cancers observed in male relatives of theBRCA2 carriers
at that age.
We studied prevalent cases; if the survival of BRCA1
or BRCA2 mutation carriers is better than that of non-
carriers, then we expect to see the prevalence of mu-
tations increasing with time since diagnosis. However,
because BRCA1-positive cases also occur at a younger
age than nonhereditary cases and because BRCA2-pos-
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Table 6
Cumulative Incidence of Cancer in First-Degree Relatives of Jewish Women with Ovarian Cancer: Carriers Versus Noncarriers
Site
CUMULATIVE INCIDENCE OF CANCER (%) TO AGE
55 Yearsa 65 Yearsa 75 Yearsa
Noncarrier Carrier Pb RRc Noncarrier Carrier Pb RRc Noncarrier Carrier Pb RRc
Breast 6.3 13.9 .006 2.41 8.1 24.1 .0001 2.95 15.8 28.3 .002 2.20
Ovary 1.9 7.2 .031 3.07 1.9 10.0 .004 4.00 4.0 10.0 .018 2.89
Prostate .0 1.5 .078  .0 1.5 .078  5.3 9.3 .109 2.47
Uterus .0 1.6 .078  .0 3.9 .011  1.1 3.9 .053 6.53
Colon .7 1.1 .593 1.54 2.3 2.2 .978 .99 5.3 5.7 .895 1.06
Pancreas .5 .3 .830 .77 1.5 1.4 .945 .95 1.5 2.9 .448 1.61
Lung .0 .3 .211  1.1 .3 .590 .54 3.1 3.4 .759 1.20
Head and neck .2 .0 .427 .00 1.3 .0 .115 .00 1.3 .0 .115 .00
Melanoma .4 .0 .250 .00 .4 .0 .250 .00 .9 .7 .582 .54
Primary site unknown .5 .4 .828 .77 .8 .9 .961 1.05 1.4 .9 .798 .80
Any:
Womend 4.0 6.3 .483 1.38 10.4 13.3 .464 1.26 19.6 21.1 .625 1.15
Women 11.4 24.0 .002 2.13 18.5 40.2 .0001 2.31 35.4 48.6 .001 1.76
Men 4.1 5.0 .852 1.10 12.6 10.2 .625 .84 31.4 29.1 .992 .97
All 7.8 15.0 .004 1.85 15.6 26.4 .0008 1.77 33.4 39.3 .011 1.44
NOTE.—Cancers in women include cancers in 368 female relatives of noncarriers and 253 female relatives of probands. Cancers in men
include cancers in 349 male relatives of noncarriers and 223 male relatives of probands.
a Kaplan-Meier estimates.
b Log-Rank test.
c Relative risks are obtained from a univariate Cox proportional hazard model. Baseline: noncarriers.
d Women with no breast or ovarian cancer. Female relatives with breast cancer or ovarian cancer are considered to be at risk for other
cancers.
itive women are older, it is necessary to control for age
at diagnosis in this comparison. To do so, we matched
each woman with a mutation-positive ovarian cancer
with a mutation-negative woman diagnosed at the same
age and compared the mutant frequencies by time
elapsed since diagnosis (table 8). The overall mutation
frequency in these subsamples are 50% (by definition),
but the frequency of BRCA1 mutations increased with
time since diagnosis. Although the trend did not reach
statistical significance, this observation supports the hy-
pothesis that the survival of women with BRCA1-
associated ovarian cancer is better than expected. No
similar trend was observed for BRCA2 mutations, sug-
gesting that the survival benefit is limited to BRCA1
carriers.
A founder mutation was not identified for 122 of 208
women. To estimate the frequency of nonfounder mu-
tations in Jewish ovarian-cancer cases, we performed
protein-truncation test analysis on the large exons of
BRCA1 and BRCA2 (which comprise the majority of
the coding region of the two genes) for these 122
women. No BRCA1 mutation was identified, and a
single truncating mutation was identified in BRCA2
(6696delTC). Although the Jewish paternal aunt of the
patient was also affected with early-onset ovarian can-
cer, further investigation of this family revealed that the
mutation was inherited from the non-Jewish mother
(fig. 6). Surprisingly the sister of the proband was di-
agnosed with early-onset bilateral cancer but was not
a carrier of the 6696delT mutation.
Discussion
We identified a very high proportion (41%) of hereditary
ovarian cancers among unselected cases of epithelial
ovarian cancer in Ashkenazi Jewish women from North
America and Israel. This fraction is much higher than
the hereditary proportions of other common adult can-
cers for any ethnic group studied to date. Ours is the
first large survey of both BRCA1 and BRCA2 mutations
in Jewish women with ovarian cancer who are unselected
for age or family history. Muto et al. (1996) found that
6 of 31 (19.3%) unselected Jewish patients with ovarian
cancer in Massachusetts carried a 185delAG mutation,
and Modan et al. (1996) found that 15 of 79 (19.0%)
Ashkenazi women with ovarian cancer in Israel carried
a 185delAG mutation. For this single mutation, our es-
timate is similar (20.5%). Three other Israeli studies re-
ported on the prevalence of BRCA1 and BRCA2 mu-
tations in Israeli Jewish women with ovarian cancer
(Abeliovich et al. 1997; Beller et al. 1997; Levy-Lehad
et al. 1997). These studies focused on women selected
either for early age at onset or a family history positive
for cancer. Abeliovich et al. (1997) found 13 of 21 (62%)
of women with ovarian cancer had one of three founding
mutations. Because these patients included women re-
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Table 7
Cumulative Incidence of Cancer in First-Degree Relatives of Jewish Women with Breast Cancer: Women Positive for BRCA1 Versus
Women Positive for BRCA2
SITE
CUMULATIVE INCIDENCE OF CANCER (%) TO AGE
55 Yearsa 65 Yearsa 75 Yearsa
BRCA1 BRCA2 Pb RRc BRCA1 BRCA2 Pb RRc BRCA1 BRCA2 Pb RRc
Breast 18.8 6.2 .022 .30 27.0 19.7 .095 .53 29.8 26.3 .174 .62
Ovary 6.8 7.7 .955 .97 8.3 12.3 .700 1.24 8.3 12.3 .700 1.24
Prostate 1.0 2.7 .618 2.00 1.0 2.7 .618 2.00 8.0 12.0 .626 1.45
Uterus 2.8 .0 .233 .00 6.6 .0 .092 .00 6.6 .0 .092 .00
Colon 1.0 1.2 .914 .88 1.0 4.4 .275 2.61 5.3 6.4 .699 1.30
Pancreas .4 .0 .450 .00 .4 2.9 .289 3.39 1.5 5.0 .308 2.46
Lung .5 .0 .450 .00 .5 .0 .450 .00 4.6 1.8 .398 .40
Head and neck .0 .0 ) ) .0 .0 ) ) .0 .0 ) )
Melanoma .0 .0 ) ) .0 .0 ) ) .0 1.8 .182 
Primary site unknown .0 1.1 .188  .0 2.5 .066  .0 2.5 .066 
Any:
Womend 8.3 3.4 .261 .42 15.1 10.6 .421 .65 21.8 19.7 .591 .79
Women 28.8 16.6 .041 .48 41.2 38.8 .249 .73 46.6 51.0 .508 .85
Men 3.0 8.9 .167 2.76 4.4 21.4 .012 4.16 23.7 39.5 .041 2.22
All 15.8 13.4 .356 .75 23.3 31.6 .605 1.14 34.9 46.3 .353 1.22
NOTE.—Cancers in women include cancers in 162 female relatives of BRCA1 carriers and 91 female relatives of BRCA2 carriers.
Cancers in men included cancers in 149 male relatives of BRCA1 carriers and 74 male relatives of BRCA2 carriers.
a Kaplan-Meier estimates.
b Log-rank test.
c Relative risks are obtained from a univariate Cox proportional hazard model. Baseline: positive for BRCA1.
d Women with no breast or ovarian cancer. Female relatives with breast cancer or ovarian cancer are considered to be at risk for other
cancers.
Table 8
Frequency of Mutations in Women with Ovarian Cancer by Time since Diagnosis
Years since Diagnosis
No. of BRCA1
Controls
No. of Patients Positive
for Mutations in
BRCA1 (%)
No. of BRCA2
Controls
No. of Patients Positive
for Mutations in
BRCA2 (%)
.0–.9 16 13 (44.8) 10 5 (33.3)
1.0–3.9 23 22 (48.9) 13 17 (56.7)
4.0–7.9 11 12 (52.2) 2 3 (60.0)
8.0–26.0 7 10 (58.8) 4 4 (50.0)
Total 57 57 (50.0) 29 29 (50.0)
P value for trend .35 .40
ferred from a cancer genetics counseling clinic, their es-
timate is higher than ours. No 5382insC mutation was
found in this sample. Levy-Lehad et al. (1997) studied
22 incident cases of ovarian cancer among Ashkenazi
women presenting to the Division of Gynecologic On-
cology at the Shaare Zedek Medical Center in Jerusalem
between September 1995 and May 1996. One of three
founder mutations was present in 10 of 22 women
(45%). The mean age at diagnosis in the three BRCA2
carriers (68.3 years) was much higher than that in the
BRCA1 carriers (50.5 years). These patients are also
described by Beller et al. (1997).
The prevalence of mutations in Ashkenazi Jews with
ovarian cancer is many times higher than in non-Jewish
patients. In a study of 374 women with ovarian cancer
in the United Kingdom, Stratton et al. (1997) estimated
that only 3.5% of all cancer cases carry a BRCA1
mutation. In a smaller study, Rubin et al. (1998) found
one BRCA2 mutation and 10 BRCA1 mutations in 113
hospital-based cases of ovarian cancer, for an overall
prevalence of 9.7%. Janezic et al. (1999) found a path-
ogenic BRCA1 mutation in only 2 of 107 unselected
ovarian-cancer cases in California. The proportions of
Jewish patients in these studies are not known.
The frequency of mutations in BRCA1 and BRCA2
in the Jewish population at large is ∼2% and is much
greater than the frequency in non-Jews. This high prev-
alence accounts, to a large extent, for the greater pop-
ulation-attributable risk observed in the Jewish popu-
lation; however, it is also possible that the risk of
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ovarian cancer associated with the Jewish founder mu-
tations exceeds that of other BRCA1 or BRCA2 mu-
tations. On the basis of the RR method, we estimate
the penetrance of ovarian cancer to be 51% for carriers
of the 185delAG mutation, 21% for carriers of the
5382insC mutation, and 14% for carriers of the
6174delT mutation. The risk estimates generated by the
kin-cohort method were much lower—but these esti-
mates were made on the basis of small numbers of cases
in relatives, and the confidence limits are wide. Fur-
thermore, the kin-cohort method depends on the ac-
curacy of the probands’ recollections. Struewing et al.
(1997) also used the kin-cohort method to estimate pen-
etrance in the Jewish population, but their estimates
were made on the basis of only 11 observed ovarian
cancers in 306 female relatives of carriers.
The Jewish founder mutations represent only three of
the hundreds of mutations in BRCA1 or BRCA2 that
have been identified to date. The risk of ovarian cancer
is believed not to be the same for all BRCA2 mutations
and varies according to the position of the mutation
along the gene. In particular, the 6174delT mutation is
in the ovarian-cancer cluster region of BRCA2 as de-
fined by Gayther et al. (1997). BRCA2 mutations out-
side this region of exon 11 are believed to carry a much
lower risk of ovarian cancer. This is consistent with
the high risk of ovarian cancer associated with the
6174delT mutation in our study. Similarly, truncating
mutations in the first two-thirds of the coding region
of BRCA1 are thought to be associated with a higher
risk of ovarian cancer than mutations in the last third
of the gene (Gayther et al. 1995). The 185delAG mu-
tation is in the extreme 5′ end of the gene, and the
5382insC mutation is in the extreme 3′ end of the gene.
In support of this hypothesis, we found the ovarian-
cancer risk to be moderately higher for carriers of the
185delAG mutation, compared with carriers of the
5382insC mutation (by the RR method).
This study suggests that the three founder mutations
account for the most of the heritability of ovarian cancer
in the Jewish population. Of 87 identified mutations,
86 were founder mutations, and the single nonfounder
mutation was inherited from a non-Jewish ancestor.
Furthermore, we found only a modest, nonsignificant
excess risk of ovarian cancer in the relatives of the mu-
tation-negative women. This suggests that most of the
familial clustering of ovarian cancer in the Jewish pop-
ulation is attributable to these three founding muta-
tions. If there are ovarian cancer–susceptibility genes
other than BRCA1 and BRCA2, their contribution will
be relatively minor in the Jewish population.
It has been reported that the risk of breast and ovarian
cancer appears to be increasing from generation to gen-
eration in some families whose members carry muta-
tions (Narod et al. 1993). The present study provided
the opportunity to directly evaluate the possibility of a
cohort effect among the carriers. We compared the risk
of breast and ovarian cancer in the mothers and sisters
of the carriers. Under the assumption that cancer risk
is increasing with birth year, we would expect that the
risk in sisters should exceed that of mothers. This was
not found, and our data set does not support the phe-
nomenon of genetic anticipation or a cohort effect.
A family history of pancreatic cancer was found to
be a risk factor for ovarian cancer. This relationship is
largely due to the impact of BRCA2. In a previous study,
BRCA2 mutations were found to be present in 3 of 26
unselected Jewish cases of pancreatic cancer (Ozcelik et
al. 1997). Our data also support the hypothesis that
male carriers of BRCA1 or BRCA2 mutations are at
increased risk of prostate cancer (Warner et al. 1999),
and we recommend prostate specific antigen screening
of men with BRCA1 or BRCA2 mutations from age 50
years. The association of BRCA1 and endometrial can-
cer has not been reported previously and warrants fur-
ther attention.
We did not see an increase in the risk of colon cancer
in the relatives of the BRCA1 or BRCA2 carriers, com-
pared with noncarriers or healthy controls. No excess
of colon cancer was seen in the family members of
BRCA2 carriers in the study of the Breast Cancer Link-
age Consortium (1999). Since the original paper by Ford
et al. (1994), colon cancer has not been found to be a
feature of the BRCA1 spectrum.
Rubin et al. (1996) reported that ovarian cancer pa-
tients with BRCA1 mutations have a better likelihood
of 10-year survival than do women without mutations,
after adjustments are made for the stage of cancer. This
study has been criticized on the basis that the selection
criteria favored long-term survivors in carriers (Brunet
et al. 1997; Modan 1997). However, a recent study
based on pathology specimens confirmed the previous
results (Boyd et al. 1999). Our data indirectly support
the hypothesis of Rubin and his colleagues thatBRCA1-
associated ovarian cancer has a better prognosis. We
found an increasing prevalence of mutations with time
elapsed since diagnosis—consistent with the notion that
BRCA1 mutations are overrepresented in long-term
ovarian-cancer survivors. It was surprising, therefore,
to find that the BRCA1 carriers commonly presented
with high-grade tumors. It may be that the high-grade,
BRCA1-positive tumors lack the capacity to repair
DNA damage and are therefore particularly sensitive to
the cytotoxic effects of chemotherapy.
We feel that our data support the position that Jewish
women with ovarian cancer should be offered testing
for BRCA1 and BRCA2 mutations. Factors that predict
the presence of a mutation include tumor grade, age at
onset, histology, and family history. Tumor grade ap-
pears to be the most discriminating of the four predictive
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factors. A mutation was found in 28% of the ovarian-
cancer cases that had no family history of breast or
ovarian cancer and in 64% of patients with a family
history of ovarian cancer. On the basis of these data,
we expect that the majority of Jewish women who de-
velop ovarian cancer in the context of a screening pro-
gram for women at high familial risk will also carry a
BRCA1 or a BRCA2 mutation. Because of the high risk
of ovarian cancer associated with each of these muta-
tions and because of the limitations of ovarian cancer
screening, we feel that the option of prophylactic oo-
phorectomy should be raised with women who carry
the mutation who have not yet developed cancer.
Struewing et al. (1995b) found a 45% reduction in the
risk of ovarian or peritoneal carcinoma following pro-
phylactic oophorectomy in high-risk women. Prospec-
tive data on the residual risk of cancer and on the com-
plications of premenopausal surgical oophorectomy are
needed. Data are emerging that prophylactic oophorec-
tomy may also be effective in reducing the risk of breast
cancer (Rebbeck et al. 1999). On the basis of the age
distributions of the mutation-positive ovarian cancers
(table 1), it may be reasonable to wait until the time of
the natural menopause to perform oophorectomy for
BRCA2 carriers, but, for maximum protection, the op-
eration should be performed at a much lower age in
women who carry BRCA1 mutations; 31 of 57 (54%)
of the ovarian cancers in carriers of BRCA1 mutations
were diagnosed before age 50 years.
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